What is Neuraxis, Inc.'s share price today?
Neuraxis, Inc. (NRXS) share price today is $6.80 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $6.80 and a day low of $6.56.What exchange does Neuraxis, Inc. stock trade on, and under what ticker symbol?
Neuraxis, Inc. stock trades on AMEX under the ticker symbol NRXS.What is Neuraxis, Inc.'s market capitalization?
Neuraxis, Inc.'s market capitalization is $82.88M as of November 5, 2026 at 2:29 AM IST.What is Neuraxis, Inc.'s price-to-earnings (P/E) ratio?
Neuraxis, Inc.'s price-to-earnings (P/E) ratio is N/A as of November 4, 2026.What is Neuraxis, Inc.'s price-to-book (P/B) ratio?
Neuraxis, Inc.'s price-to-book (P/B) ratio is 13.30 as of November 4, 2026.Can Indian investors buy Neuraxis, Inc. shares?
Yes, You can buy Neuraxis, Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Neuraxis, Inc. shares from India?
Indian investors can buy Neuraxis, Inc. shares in three steps: 1. Search Neuraxis, Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Neuraxis, Inc. shares for Indian investors?
Since Neuraxis, Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Neuraxis, Inc. shares via Tickertape?
Indian investors can start investing in Neuraxis, Inc. (NRXS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.4688 shares at the current price of $6.80.
$
₹
$6.803.46% (+0.22)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
13.30
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-0.72
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
-144.44%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 1 analyst's reports
Buy1 analyst
Hold0 analyst
Sell0 analyst
Price Upside
+60.35%
Earnings Growth
+14.61%
Rev. Growth
+132.54%
Company Profile
Company Profile
ABBV
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$6.86Baseline
Analyst Target - 1 year
Target$11+60.35%
All values in $
2026
Current$6.86Baseline
Analyst Target - 1 year
Target$11+60.35%
All values in $
Revenue Forecast
Revenue Forecast
Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 132.54% growth, versus a trailing 3-year CAGR of 9.96%.
2025
Current$3.56Baseline
Forecast for Dec 2026
High$8.3+132.54%
Average$8.3+132.54%
Low$8.3+132.54%
All values in $ Million
2025
Current$3.56Baseline
Forecast for Dec 2026
High$8.3+132.54%
Average$8.3+132.54%
Low$8.3+132.54%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-0.89Baseline
Forecast for Dec 2026
High$-0.76+14.61%
Average$-0.76+14.61%
Low$-0.76+14.61%
All values in $
2025
Current$-0.89Baseline
Forecast for Dec 2026
High$-0.76+14.61%
Average$-0.76+14.61%
Low$-0.76+14.61%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.64 | 0.61 | 0.66 | 0.76 | 0.89 | 0.89 | 0.81 | 0.96 | 1.60 | 1.92 |
Gross Profit | 0.57 | 0.53 | 0.56 | 0.65 | 0.75 | 0.74 | 0.67 | 0.82 | 1.38 | 1.65 |
| Net Income | -2.12 | -2.91 | -1.75 | -1.44 | -2.27 | -1.69 | -2.12 | -1.70 | -1.76 | -2.27 |
| Net Profit Margin | -327.95% | -477.13% | -263.30% | -190.22% | -254.41% | -189.06% | -261.61% | -176.49% | -109.54% | -118.07% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Neuraxis, Inc. | - | 13.30 | - |
| AbbVie Inc | 50.67 | 50.45 | 0.60 |
| Amgen Inc | 28.90 | 21.55 | 2.77 |
Price Comparison
Price Comparison
Compare NRXS with any stock or ETFCompare NRXS with any stock or ETF
Comparing from
NRXS
ABBV
AMGN
The 12-month consensus target implies 60.35% growth, versus a trailing 3-year CAGR of 44.79%.